{
    "root": "2f890f19-c796-51b2-e063-6394a90af48d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lamivudine",
    "value": "20250304",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "LAMIVUDINE",
            "code": "2T8Q726O95"
        }
    ],
    "indications": "lamivudine nucleoside analogue indicated combination antiretroviral agents treatment human immunodeficiency virus type 1 ( hiv-1 ) infection . limitations : product hiv-1 hbv .",
    "contraindications": "adults : 300 mg daily , administered either 150 mg twice daily 300 mg daily . ( 2.1 ) pediatric patients aged 3 months older : administered either twice daily . dose calculated body weight ( kg ) exceed 300 mg daily . ( 2.2 ) patients renal impairment : doses lamivudine must adjusted accordance renal function . ( 2.3 )",
    "warningsAndPrecautions": "lamivudine tablets usp , 300 mg white , circular , biconvex , film coated tablets `` l300 `` engraved one side plain side ndc : 70518-2070-00 packaging : 30 1 blister pack store lamivudine tablets 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . protect light . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "lamivudine tablets contraindicated patients previous hypersensitivity reaction lamivudine .",
    "indications_original": "Lamivudine is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.\n                  \n                     Limitations of Use:\n                  \n                  \n                     The dosage of this product is for HIV-1 and not for HBV.",
    "contraindications_original": "Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily. (2.1) Pediatric Patients Aged 3 Months and Older: Administered either once or twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily. (2.2) Patients with Renal Impairment: Doses of Lamivudine must be adjusted in accordance with renal function. (2.3)",
    "warningsAndPrecautions_original": "Lamivudine Tablets USP, 300 mg\n                  White, circular, biconvex, film coated tablets \"L300\" engraved on one side and plain on other side\n                  \n                  NDC: 70518-2070-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store lamivudine tablets at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Protect from light.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Lamivudine Tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine."
}